Estrogenic compounds as anti-mitotic agents

Details Estrogenic compounds as anti-mitotic agents Estrogenic compounds as anti-mitotic agents

2007-11-06

2007-11-06

Badio, Barbara P. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

11402386

ABSTRACT:
The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.

REFERENCES:
patent: 2584271 (1952-02-01), Huffman
patent: 2846453 (1958-08-01), Hoehn
patent: 3166577 (1965-01-01), Ringold et al.
patent: 3410879 (1968-11-01), Smith et al.
patent: 3470218 (1969-09-01), Farah
patent: 3492321 (1970-01-01), Crabbe
patent: 3496272 (1970-02-01), Kruger
patent: 3562260 (1971-02-01), De Ruggieri et al.
patent: 3950437 (1976-04-01), Imamura et al.
patent: 3956348 (1976-05-01), Hilscher
patent: 4172132 (1979-10-01), Draper et al.
patent: 4212864 (1980-07-01), Tax
patent: 4307086 (1981-12-01), Tax
patent: 4444767 (1984-04-01), Torelli et al.
patent: 4522758 (1985-06-01), Ward et al.
patent: 4552758 (1985-11-01), Murphy et al.
patent: 4634705 (1987-01-01), DeBernardis et al.
patent: 4743597 (1988-05-01), Javitt et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5504074 (1996-04-01), D'Amato et al.
patent: 5621124 (1997-04-01), Seilz et al.
patent: 5643900 (1997-07-01), Fotsis et al.
patent: 5661143 (1997-08-01), D'Amato et al.
patent: 5750576 (1998-05-01), DeGregorio et al.
patent: 5892069 (1999-04-01), D'Amato et al.
patent: 5919459 (1999-07-01), Nacy et al.
patent: 6011023 (2000-01-01), Clark et al.
patent: 6011024 (2000-01-01), Reed et al.
patent: 6528676 (2003-03-01), D'Amato et al.
patent: 6723858 (2004-04-01), D'Amato et al.
patent: 6908910 (2005-06-01), D'Amato et al.
patent: 6930128 (2005-08-01), D'Amato et al.
patent: 2002/0165212 (2002-11-01), D'Amato et al.
patent: 2003/0096800 (2003-05-01), D'Amato et al.
patent: 2004/0072813 (2004-04-01), D'Amato et al.
patent: 1907330 (1969-10-01), None
patent: 3625315 (1988-01-01), None
patent: 0166937 (1986-08-01), None
patent: 857080 (1960-12-01), None
patent: 857081 (1960-12-01), None
patent: 1570597 (1980-07-01), None
patent: 2252498 (1992-08-01), None
patent: 39-5480 (1961-03-01), None
patent: 41 000100 (1966-01-01), None
patent: 42-928 (1967-01-01), None
patent: 62-135472 (1987-06-01), None
patent: 63090763 (1988-04-01), None
patent: 63-119500 (1988-05-01), None
patent: 04-046120 (1992-02-01), None
patent: WO 87/02367 (1987-04-01), None
patent: WO 88/03151 (1988-05-01), None
patent: WO 88/08002 (1988-10-01), None
patent: WO 90/15816 (1990-12-01), None
patent: WO 93/03729 (1993-03-01), None
patent: WO 93/10805 (1993-06-01), None
patent: WO 93/19746 (1993-10-01), None
patent: WO 95/04535 (1995-02-01), None
Seegers et al., “The cytotoxic effects of estradiol-17beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells.” J. Steroid Biochem., vol. 32(6), pp. 797-809, 1989.
Schumacher et al., “The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors.” J. Cancer Res. Clin. Oncol., vol. 127, pp. 405-410, 2001.
Pribluda et al., “2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate.” Cancer and Metastasis Reviews, vol. 19, pp. 173-179, 2000.
Hori, A. et al., Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody Against Human Basic Fibroblasts Growth Factor,Cancer Research,vol./Iss:51, pp. 6180-6184, Date: Nov. 15, 1991.
Kim, K.J. et al., Inhibition of Vascular Endothelial Growth Factor-induced Angiogenesis Suppresses Tumor Growth In Vivo,Nature,vol./Iss:362, pp. 841-844, Date: Apr. 29, 1993.
Yang, Ning-Sun, Gene Transfer into Mammalian Somatic Cells/l Vivo,Critical Reviews in Biotechnology,vol./Iss:12(4), pp. 335-356, Date: 1992.
U.S. Appl. No. 09/644,387, filed Aug. 23, 2000.
U.S. Appl. No. 11/235,574, filed Sep. 26, 2005.
U.S. Appl. No. 11/347,880, filed Feb. 6, 2006.
U.S. Appl. No. 09/939,208, filed Aug. 24, 2001.
U.S. Appl. No. 11/118,852, filed Apr. 29, 2005.
U.S. Appl. No. 10/856,340, filed May 28, 2004.
U.S. Appl. No. 10/918,627, filed Aug. 12, 2004.
U.S. Appl. No. 11/230,375, filed May 19, 2005.
U.S. Appl. No. 10/789,471, filed Feb. 27, 2004.
U.S. Appl. No. 11/077,977, filed Mar. 11, 2005.
U.S. Appl. No. 11/288,989, filed Nov. 29, 2005.
Lilopristone/(1-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxy-1-propenyl) estra-4,9-diene-3-one; AK 98734,Dictionary of Drugs(1990),Dict. of Steroids(1991), Dict. of Org. Cmpds(6th Ed) (1996),Dict. of Pharm Agents(1997), Date: 1990.
(Paragraphs 583-584),The Merck Index 11th Edition,pp. 88, Date: 1989.
Research Plus Catalog,pp. 50-58, Date: 1993.
Aboulwafa et al., Synthesis and evaluation for uterotrophic and antiimplantation activities of 2-substituted estradiol derivatives,Steroids,vol./Iss: 57, pp. 199-204, Date: Apr. 1992.
Adams, E.F. et al., Steroidal regulation of oestradiol-17B dehydrogenase activity of the human breast cancer cell line MCF-7 (Chemical Abstracts Doc No. 109:32325, 1988),Journal of Endocrinology,vol./Iss: 118(1), pp. 149-154, Date: Jul. 1988.
Algire, G.H. et al., Title:Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants,Journal of the National Cancer Institute,vol./Iss: 6, pp. 73-85, Date: Aug. 1945.
Aliev et al., 54929q Synthesis of cycloalkyl derivatives of dihydric phenols and their ethers,Chemical Abstracts,vol./Iss: 72, pp. 370, Date: 1970.
Banik et al., Orally Active Long-Acting Estrogen (AY-20,121) (3-(2-propynyloxy)-estra-1,3,5,(10)-triene-17. beta.-ol trimethylacetate) (Identifier only),Steroids,vol./Iss: 16(3), pp. 289-296, Date: 1970.
Bardon et al., Steroid Receptor-Mediated Cytotoxicity of an Antiestrogen and an Antiprogestin in Breast Cancer Cells (Abstract only),Cancer Research,vol./Iss:47 (5), pp. 1441-1448, Date: Mar. 1, 1987.
Barnes et al., Tumor Necrosis Factor Production in Patients with Leprosy,Infection and Immunity,vol./Iss:60 (4), pp. 1441-1446, Date: Apr. 1992.
Bhat et al., Estradiol-induced Mitotic Inhibition in the Bursa of Fabricius of Male Domestic Duckling (Chemical Abstracts Doc. No. 98:31837, 1982),Mikroskopie,vol./Iss:39, pp. 113-117, Date: May 1982.
Bhattacharyya et al., Tubulin aggregation and disaggregation: Mediation by two distinct vinblastine-binding sites,National Academy of Sciences,vol./Iss:73 (7), pp. 2375-2378, Date: Jul. 1976.
Bindra et al., Studies in Antifertility Agents.8.Seco Steroids. 2. 5,6-Secoestradiol and Some Related Compounds,Journal of Medicinal Chemistry,vol./Iss:18 (9), pp. 921-925, Date: 1975.
Blickenstaff et al., Estrogen-Catharanthus (Vinca) Alkaloid Conjugates (Chemical Abstracts Doc. No. 94:114277, 1981),Cytotoxic Estrogens in Hormone Receptive Tumors,pp. 89-105, Date: 1980.
Blickenstaff et al., Synthesis of Some Analogs of Estradiol,Steroids,vol./Iss:46 (4,5), pp. 889-902, Date: Oct. 1985.
Boyce et al., Some Preliminary Synthetical Studies with 5,6,7,8-Tetra-hydro-8-methylindane-1,5-dione,Unknown,pp. 4547-4553, Date: 1960.
Boye et al., 185. Deaminocolchinyl Methyl Ether: Synthesis from 2,3,4,4′-Tetramethoxybiphenyl- 2-carbaldehyde. Comparison of Antitubulin Effects of Deaminocolchinyl Methyl Ether and Dehydro Analogs,Helvetica Chimica Acta,vol./Iss:72, pp. 1690-1696, Date: 1989.
Brandi et al., Bone endothelial cells as estrogen targets (Abstract only),Calcif. Tissue Int.,vol./Iss:53 (5), pp. 312-317, Date: 1993.
Brem, H. et al., Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas,Journal of Neurosurgery,vol./Iss:74, pp. 441-446, Date: Mar. 1, 1991.
Brosens et al., Comparative Study of the Estrogenic Effect of Ethinylestradiol and Mestranol on the Endometrium,Contracteption,(Laboratory for Gynecological Physiopathology), vol./Iss:14 (6), pp. 679-685, Date: Dec. 1, 1976.
Cambie et al., Aromatic Steroids. Part II. Chromium Trioxide Oxidation of Some Oestra-1,3-5(10

Affiliated with

Also associated with

Rating

Estrogenic compounds as anti-mitotic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Estrogenic compounds as anti-mitotic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estrogenic compounds as anti-mitotic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3879304